Reference : One-year and longer dual antiplatelet therapy after an acute coronary syndrome: a Bel...
Scientific journals : Article
Human health sciences : Cardiovascular & respiratory systems
One-year and longer dual antiplatelet therapy after an acute coronary syndrome: a Belgian position paper.
Sinnaeve, Peter R. [> >]
Desmet, Walter [> >]
Descamps, Olivier [> >]
Gevaert, Sofie [> >]
De Backer, Guy [> >]
Kolh, Philippe mailto [Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biochimie et physiologie générales, humaines et path. >]
Vrolix, Mathias [> >]
Van De Borne, Philippe [> >]
De Meester, Antoine [> >]
Claeys, Marc J. [> >]
Beauloye, Christophe [> >]
Acta Cardiologica
Yes (verified by ORBi)
[en] Dual antiplatelet therapy ; STEMI ; myocardial infarction
[en] Acute coronary syndrome patients receive DAPT up to one year after their initial event. Exceptions to the guideline-recommended one-year rule, however, are not uncommon. The reasoning behind shorter treatments, such as unacceptable bleeding risk or urgent surgery, should be well documented in the patient's charts and discharge letter. Based on recent evidence, patients at high risk for repetitive events should continue on low-dose ticagrelor without a significant interruption at one year and indefinitely in the absence of excess bleeding risk. As there is currently no reimbursement, policy makers and insurers should be made aware of the continuing risk and unmet clinical need in this patient population. Nevertheless, many unsolved questions need to be answered, both through additional analyses from recent trials such as PEGASUS-TIMI 54 or DAPT, as well as new carefully designed clinical studies.
Researchers ; Professionals

File(s) associated to this reference

Fulltext file(s):

Restricted access
sinnaeve_2017_ActaCardio_DAPT_position.pdfPublisher postprint2.5 MBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.